PMCC PMCC

Search tips
Search criteria

Advanced
Results 1-15 (15)
 

Clipboard (0)
None

Select a Filter Below

Journals
Year of Publication
2.  ABO genotyping: the quest for clinical applications 
Blood Transfusion  2013;11(1):6-9.
doi:10.2450/2012.0250-12
PMCID: PMC3557469  PMID: 23245718
3.  Red blood cell preservation by droplet freezing with polyvinyl pyrrolidone or sucrose/dextrose and by bulk freezing with glycerol 
Transfusion  2011;51(12):2703-2708.
Background
Red blood cell (RBC) preservation is essential to transfusion medicine. Many blood group reference laboratories need a method to preserve rare blood samples for serologic testing at a later date. This study offers a comparison of three common cryoprotective agents and protocols used today: bulk preservation with glycerol and droplet freezing with sucrose/dextrose (S+D) or polyvinyl pyrrolidone (PVP).
Study design and methods
Human blood from 14 volunteers was collected and frozen at set intervals over two weeks with PVP, S+D, or glycerol. The frozen RBCs were later thawed and the percentage of surviving RBCs was determined. Detailed protocols and an instructional video are supplied.
Results
Over a two week period, RBCs preserved with glycerol and thawed with a widely used protocol showed a recovery of 41 ± 16 % (mean ± standard deviation) while those thawed with a modified glycerol protocol showed a recovery of 76 ± 8 %. RBCs preserved by droplet freezing with S+D showed a recovery of 56 ± 11 % while those preserved by droplet freezing with PVP showed a recovery of 85 ± 6 %. Recovery values were similar with ethylenediaminetetraacetic acid (EDTA) or heparin anticoagulants, differing freezing rates, and varying droplet volumes.
Conclusion
Droplet freezing with PVP offered the greatest recovery. While bulk freezing with glycerol can be effective too, droplet freezing may be a more convenient method overall. It requires less effort to thaw, needs much less storage room, and allows blood group laboratories to be frugal with thawing rare samples.
doi:10.1111/j.1537-2995.2011.03258.x
PMCID: PMC3470803  PMID: 21790629
5.  Organization and management of an accredited Specialist in Blood Bank (SBB) Technology program 
Transfusion  2010;50(7 Pt 2):1612-1617.
Background
Specialists in Blood Bank (SBB) Technology play important roles in blood banks, transfusion services, regulatory agencies, educational institutions and other facilities where expertise in blood banking, transfusion medicine, cellular therapy, and tissue transplantation is required.
Study design
Review of pathways that qualify applicants for a national examination administered by the American Society of Clinical Pathology (ASCP) to become a certified specialist and outcomes of accredited programs. Description of a face-to-face, accredited program including review of management topics included in curriculum.
Results
The first examination was administered in 1954. As of December 2009, the total number certified SBBs was 5,124. There are currently 16 accredited SBB programs in the United States. The programs vary in mode of delivery, length of program, number of students accepted and organization of program officials and faculty but all must follow specific standards and guidelines in order to be accredited.
Conclusion
Students who successfully complete SBB programs have a higher passing rate than those who attempt the certification examination and have not participated in a program. Students can choose among a variety of programs that differ widely in the way they are managed. The role of management in an SBB program ranges from attracting and retaining individuals, to maintaining an accredited program to finally graduating individuals who not only pass the certification examination but who also confidently contribute to the field.
doi:10.1111/j.1537-2995.2010.02737.x
PMCID: PMC3390912  PMID: 21175473
6.  Fresh blood for transfusion: how old is too old for red blood cell units? 
Blood Transfusion  2012;10(3):247-251.
doi:10.2450/2012.0105-12
PMCID: PMC3417719  PMID: 22889813
7.  Expression of blood group genes by mesenchymal stem cells 
British journal of haematology  2011;153(4):520-528.
Incompatible blood group antigens are highly immunogenic and can cause graft rejections. Focusing on distinct carbohydrate- and protein-based membrane structures, defined by blood group antigens, we investigated human bone marrow-derived mesenchymal stem cells (MSCs) cultured in human serum. The presence of H (CD173), ABO, RhD, RhCE, RhAG, Kell, urea transporter type B (SLC14A1, previously known as JK), and Duffy antigen receptor of chemokines (DARC) was evaluated at the levels of genome, transcriptome and antigen. Fucosyltransferase-1 (FUT1), RHCE, KEL, SLC14A1 (JK) and DARC mRNA were transcribed in MSCs. FUT1 mRNA transcription was lost during differentiation. The mRNA transcription of SLC14A1 (JK) decreased during chondrogenic differentiation, while that of DARC increased during adipogenic differentiation. All MSCs synthesized SLC14A1 (JK) but no DARC protein. However, none of the protein antigens tested occurred on the surface, indicating a lack of associated protein function in the membrane. As A and B antigens are neither expressed nor adsorbed, concerns of ABO compatibility with human serum supplements during culture are alleviated. The H antigen expression by GD2dim+ MSCs identified two distinct MSC subpopulations and enabled their isolation. We hypothesize that GD2dim+H+ MSCs retain a better “stemness”. Because immunogenic blood group antigens are lacking, they cannot affect MSC engraftment in vivo, which is promising for clinical applications.
doi:10.1111/j.1365-2141.2011.08652.x
PMCID: PMC3080447  PMID: 21418181
stem cell transplantation; mesenchymal cells; blood groups; H antigen; CD173
8.  Molecular genetics and clinical applications for RH 
Rhesus is the clinically most important protein-based blood group system. It represents the largest number of antigens and the most complex genetics of the 30 known blood group systems. The RHD and RHCE genes are strongly homologous. Some genetic complexity is explained by their close chromosomal proximity and unusual orientation, with their tail ends facing each other. The antigens are expressed by the RhD and the RhCE proteins. Rhesus exemplifies the correlation of genotype and phenotype, facilitating the understanding of general genetic mechanisms. For clinical purposes, genetic diagnostics of Rhesus antigens will improve the cost-effective development of transfusion medicine.
doi:10.1016/j.transci.2010.12.013
PMCID: PMC3042511  PMID: 21277262
Rhesus; blood group; molecular genetics; molecular diagnostic; transfusion
9.  Codon usage in vertebrates is associated with a low risk of acquiring nonsense mutations 
Background
Codon usage in genomes is biased towards specific subsets of codons. Codon usage bias affects translational speed and accuracy, and it is associated with the tRNA levels and the GC content of the genome. Spontaneous mutations drive genomes to a low GC content. Active cellular processes are needed to maintain a high GC content, which influences the codon usage of a species. Loss-of-function mutations, such as nonsense mutations, are the molecular basis of many recessive alleles, which can greatly affect the genome of an organism and are the cause of many genetic diseases in humans.
Methods
We developed an event based model to calculate the risk of acquiring nonsense mutations in coding sequences. Complete coding sequences and genomes of 40 eukaryotes were analyzed for GC and CpG content, codon usage, and the associated risk of acquiring nonsense mutations. We included one species per genus for all eukaryotes with available reference sequence.
Results
We discovered that the codon usage bias detected in genomes of high GC content decreases the risk of acquiring nonsense mutations (Pearson's r = -0.95; P < 0.0001). In the genomes of all examined vertebrates, including humans, this risk was lower than expected (0.93 ± 0.02; mean ± SD) and lower than the risk in genomes of non-vertebrates (1.02 ± 0.13; P = 0.019).
Conclusions
While the maintenance of a high GC content is energetically costly, it is associated with a codon usage bias harboring a low risk of acquiring nonsense mutations. The reduced exposure to this risk may contribute to the fitness of vertebrates.
doi:10.1186/1479-5876-9-87
PMCID: PMC3123582  PMID: 21651781
10.  Rare gems: null phenotypes of blood groups 
Blood Transfusion  2010;8(1):2-4.
doi:10.2450/2009.0133-09
PMCID: PMC2809504  PMID: 20104271
11.  The Bloodgen Project of the European Union, 2003–2009 
Summary
The Bloodgen project was funded by the European Commission between 2003 and 2006, and involved academic blood centres, universities, and Progenika Biopharma S.A., a commercial supplier of genotyping platforms that incorporate glass arrays. The project has led to the development of a commercially available product, BLOODchip, that can be used to comprehensively genotype an individual for all clinically significant blood groups. The intention of making this system available is that blood services and perhaps even hospital blood banks would be able to obtain extended information concerning the blood group of routine blood donors and vulnerable patient groups. This may be of significant use in the current management of multi-transfused patients who become alloimmunised due to incomplete matching of blood groups. In the future it can be envisaged that better matching of donor-patient blood could be achieved by comprehensive genotyping of every blood donor, especially regular ones. This situation could even be extended to genotyping every individual at birth, which may prove to have significant long-term health economic benefits as it may be coupled with detection of inborn errors of metabolism.
doi:10.1159/000218192
PMCID: PMC2980524  PMID: 21113258
BLOODchip; Blood groups; Blood group antigens
12.  A rewarding fresh look at routine blood group data 
Blood Transfusion  2008;6(4):182-183.
doi:10.2450/2008.0043-08
PMCID: PMC2626910  PMID: 19112731
13.  The genetics of the Rhesus blood group system* 
Blood Transfusion  2007;5(2):50-57.
doi:10.2450/2007.0011-07
PMCID: PMC2535884  PMID: 19204754
Rhesus; blood group; molecular diagnostic; transfusion; pregnancy
14.  RHD allele distribution in Africans of Mali 
BMC Genetics  2003;4:14.
Background
Aberrant and non-functional RHD alleles are much more frequent in Africans than in Europeans. The DAU cluster of RHD alleles exemplifies that the alleles frequent in Africans have evaded recognition until recently. A comprehensive survey of RHD alleles in any African population was lacking.
Results
We surveyed the molecular structure and frequency of RHD alleles in Mali (West Africa) by evaluating 116 haplotypes. Only 69% could be attributed to standard RHD (55%) or the RHD deletion (14%). The aberrant RHD allele DAU-0 was predicted for 19%, RHDΨ for 7% and Ccdes for 4% of all haplotypes. DAU-3 and the new RHD allele RHD(L207F), dubbed DMA, were found in one haplotype each. A PCR-RFLP for the detection of the hybrid Rhesus box diagnostic for the RHD deletion in Europeans was false positive in 9 individuals, including all carriers of RHDΨ . Including two silent mutations and the RHD deletion, a total of 9 alleles could be differentiated.
Conclusion
Besides standard RHD and the RHD deletion, DAU-0, RHDΨ and Ccdes are major alleles in Mali. Our survey proved that the most frequent alleles of West Africans have been recognized allowing to devise reliable genotyping and phenotyping strategies.
doi:10.1186/1471-2156-4-14
PMCID: PMC222912  PMID: 14505497
Rhesus; Rh; partial D antigen; red cell antigen; RHD gene; genotyping
15.  RHD positive haplotypes in D negative Europeans 
BMC Genetics  2001;2:10.
Background
Blood group genotyping is increasingly utilized for prenatal diagnosis and after recent transfusions, but still lacks the specificity of serology. In whites, the presence of antigen D is predicted, if two or more properly selected RHD-specific polymorphism are detected. This prediction must fail, if an antigen D negative RHD positive allele is encountered. Excluding RHDψ and CdeS frequent only in individuals of African descent, most of these alleles are unknown and the population frequency of any such allele has not been determined.
Methods
We screened 8,442 antigen D negative blood donations by RHD PCR-SSP. RHD PCR positive samples were further characterized by RHD exon specific PCR-SSP or sequencing. The phenotype of the identified alleles was checked and their frequencies in Germans were determined.
Results
We detected 50 RHD positive samples. Fifteen samples harbored one of three new Del alleles. Thirty samples were due to 14 different D negative alleles, only 5 of which were previously known. Nine of the 14 alleles may have been generated by gene conversion in cis, for which we proposed a mechanism triggered by hairpin formation of chromosomal DNA. The cumulative population frequency of the 14 D negative alleles was 1:1,500. Five samples represented a D+/- chimera, a weak D and three partial D, which had been missed by routine serology; two recipients transfused with blood of the D+/- chimera donor became anti-D immunized.
Conclusion
The results of this study allowed to devise an improved RHD genotyping strategy, the false-positive rate of which was lower than 1:10,000. The number of characterized RHD positive antigen D negative and Del alleles was more than doubled and their population frequencies in Europe were defined.
doi:10.1186/1471-2156-2-10
PMCID: PMC37267  PMID: 11495631

Results 1-15 (15)